Biotech Co. Sues Sandoz Over Remodulin Generic

Law360, New York (March 15, 2012, 1:54 PM EDT) -- United Therapeutics lodged a patent infringement suit in New Jersey federal court on Thursday seeking to stop Sandoz Inc. from launching a generic version of United Therapeutics' pulmonary arterial hypertension treatment Remodulin.

The Maryland-based biotechnology company brought its complaint after Sandoz sought federal approval of an abbreviated new drug application to make and sell a generic version of Remodulin throughout the U.S. before the expiration of United Therapeutics’ three patents.

“United Therapeutics intends to vigorously enforce its intellectual property rights relating to Remodulin, including the three...
To view the full article, register now.